Company Profile
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest News

Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls

TransMedics Group (TMDX) Stock Looks Below Fair Value On Earnings

TransMedics Group (TMDX) Could Be 19% Undervalued If Its Growth Narrative Holds

TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?

2 Stocks Down 28% and 34% to Buy and Hold
TransMedics Names Fernando Araujo as CFO; Maintains 2026 Revenue Outlook
Related stocks
Key Metrics & Overview
Detailed metrics & financial data of the company
🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data